Using our patent-protected dry fog technology, and the application of our N-List disinfectant InstaPURE (EPA Reg # 70299-19), we obliterate the presence of viruses, including the human coronavirus causing COVID-19.
For additional peace of mind (and for a slight upcharge), we can follow our InstaPURE dry fog application with an additional EPA-registered N-List product wipedown for high-touch surfaces for, then cap it all off with the application of EverPURE, a low-level disinfectant with electrostatic antimicrobial properties. We call this three-step process the "VIRUS SCRUB."
The Novel Coronavirus (SARS-CoV-2) is an "enveloped virus." Both InstaPURE and EverPURE are sufficient to denature enveloped viruses and non-enveloped viruses like H1N1, avian flu, and noroviruses, and they require very little dwell time. An entire building can typically be treated in one day and provide safety for anyone worried about getting the virus. While preventative treatment of a facility will not prevent person-to-person infections and does not replace the need to wear a facemask and wash your hands, it will help prevent surface-to-person infections.
If you need pricing for preventative maintenance of your home, office, school, or facility, call us at 720-487-1970 or book online
1. The product should be an EPA-registered, hospital/healthcare or broad-spectrum disinfectant with directions for use on hard, porous or non-porous surfaces.
2. The currently accepted product label (from an EPA registered product as described above should have disinfectant efficacy claims against at least one of the following viral pathogen groupings: a) A product should be approved by EPA to inactivate at least one large or one small non-enveloped virus to be eligible for use against an enveloped emerging viral pathogen. b) A product should be approved by EPA to inactivate at least one small, non-enveloped virus to be eligible for use against a large, non-enveloped emerging viral pathogen. c) A product should be approved by EPA to inactivate at least two small, non-enveloped viruses to be eligible for use against a small, non-enveloped emerging viral pathogen.
InstaPURE is already on the N-List for SARS-CoV-2. EverPURE qualifies under these EPA guidelines according to verified research and their label claims, but are still in the months-long process of being added to the N-List for SARS-CoV-2 and having the EPA master label appropriately updated.
Below you can find all of the resource material referenced in the guidelines.
For further research on disrupting an enveloped virus, visit Flagship Inc, H1N1 Study, and PAA Bacteria and Virus Testing